Orion Ventures invests in Estonian biotech company Vectiopep

The Lithuanian venture capital fund Orion Ventures has invested in Estonian the biotechnology company Vectiopep, which has developed a technology for the therapeutic delivery of mRNA to patients, enabling the use of immunotherapy in a new way of treating cancer.

Vectiopep has developed an innovative technology that allows the transmission of a molecular message to the immune system that cannot be delivered using existing technologies. The delivered mRNA teaches the immune system to seek out and kill cancer cells.

The startup was founded in 2022 by Kaido Kurrikoff and Piret Arukuusk. It is based in Tartu.

Orion Ventures is a Lithuanian corporate venture capital fund that invests in early-stage startups. It was established in 2021 as an employee fund of the investment banking firm Orion Securities.